Clinical Trials Browser

Phase 1/2 × pirtobrutinib × 30 days × Clear all

NCT04623541 2026-03-04

EPCORE™ CLL-1

Phase 1/2 Active not recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell